Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.

Xia CQ, Zhang P, Li S, Yuan L, Xia T, Xie C, Clare-Salzler MJ.

PLoS One. 2014 May 16;9(5):e97694. doi: 10.1371/journal.pone.0097694.

2.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107.

PMID:
18427551
3.

Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.

Fred RG, Boddeti SK, Lundberg M, Welsh N.

Clin Sci (Lond). 2015 Jan;128(1):17-28. doi: 10.1042/CS20130560.

PMID:
24865476
4.

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.

Okabe S, Tauchi T, Katagiri S, Tanaka Y, Ohyashiki K.

J Hematol Oncol. 2014 Apr 28;7:37. doi: 10.1186/1756-8722-7-37.

5.

Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.

Mokhtari D, Al-Amin A, Turpaev K, Li T, Idevall-Hagren O, Li J, Wuttke A, Fred RG, Ravassard P, Scharfmann R, Tengholm A, Welsh N.

Diabetologia. 2013 Jun;56(6):1327-38. doi: 10.1007/s00125-013-2868-2.

PMID:
23462796
6.

Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.

Shen Q, Liu S, Chen Y, Yang L, Chen S, Wu X, Li B, Lu Y, Zhu K, Li Y.

J Hematol Oncol. 2013 Sep 3;6:64. doi: 10.1186/1756-8722-6-64.

7.

A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.

Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J.

Oncogene. 2009 Mar 12;28(10):1285-97. doi: 10.1038/onc.2008.479.

8.

AMP-activated protein kinase and pancreatic/duodenal homeobox-1 involved in insulin secretion under high leucine exposure in rat insulinoma beta-cells.

Zhang X, Sun N, Wang L, Guo H, Guan Q, Cui B, Tian L, Gao L, Zhao J.

J Cell Mol Med. 2009 Apr;13(4):758-70. doi: 10.1111/j.1582-4934.2009.00656.x.

9.

Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E beta-cells and human islets through a SIRT1-dependent mechanism.

Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P.

J Biol Chem. 2011 Feb 25;286(8):6049-60. doi: 10.1074/jbc.M110.176842.

10.

c-Abl mediates angiotensin II-induced apoptosis in podocytes.

Chen X, Ren Z, Liang W, Zha D, Liu Y, Chen C, Singhal PC, Ding G.

J Mol Histol. 2013 Oct;44(5):597-608. doi: 10.1007/s10735-013-9505-8.

11.

TCF2 attenuates FFA-induced damage in islet β-cells by regulating production of insulin and ROS.

Quan X, Zhang L, Li Y, Liang C.

Int J Mol Sci. 2014 Jul 30;15(8):13317-32. doi: 10.3390/ijms150813317.

12.

Chronic leucine exposure results in reduced but reversible glucose-stimulated insulin secretion in INS-1 cells.

Zhang X, Han W, Jiang X, Li M, Gao L, Zhao JJ.

Mol Med Rep. 2014 Jun;9(6):2554-8. doi: 10.3892/mmr.2014.2122.

PMID:
24715028
13.

Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.

Lee J, Shen P, Zhang G, Wu X, Zhang X.

Biomed Pharmacother. 2013 Mar;67(2):157-63. doi: 10.1016/j.biopha.2012.10.017.

PMID:
23201011
14.

PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells.

Kim HS, Hwang YC, Koo SH, Park KS, Lee MS, Kim KW, Lee MK.

PLoS One. 2013;8(1):e50128. doi: 10.1371/journal.pone.0050128.

15.

Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.

Alpay K, Farshchian M, Tuomela J, Sandholm J, Aittokallio K, Siljamäki E, Kallio M, Kähäri VM, Hietanen S.

PLoS One. 2014 Aug 22;9(8):e105526. doi: 10.1371/journal.pone.0105526.

16.

Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.

Hinchcliff M, Huang CC, Ishida W, Fang F, Lee J, Jafari N, Wilkes M, Bhattacharyya S, Leof E, Varga J.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S86-96. Erratum in: Clin Exp Rheumatol. 2014 Jan-Feb;32(1):150.

17.

Protein kinase G increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-Abl tyrosine kinase.

Stephens RS, Servinsky LE, Rentsendorj O, Kolb TM, Pfeifer A, Pearse DB.

Am J Physiol Cell Physiol. 2014 Mar 15;306(6):C559-69. doi: 10.1152/ajpcell.00375.2012.

18.

Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.

O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93.

19.

Abl family kinases regulate endothelial barrier function in vitro and in mice.

Chislock EM, Pendergast AM.

PLoS One. 2013 Dec 19;8(12):e85231. doi: 10.1371/journal.pone.0085231.

20.

Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C.

Blood. 2005 Apr 15;105(8):3303-11.

Items per page

Supplemental Content

Support Center